CLINICAL EXPERIENCE OF COMBINED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER

Treatment of patients with metastatic colorectal cancer (mCRC)  is one of the priority questions in oncology. Despite the significant progress in chemotherapy treatment, development of target agents is the only way of further improvement of the results. Bevacizumab (Avastin) is the first biologic de...

Full description

Saved in:
Bibliographic Details
Published inТазовая хирургия и онкология no. 2; pp. 48 - 51
Main Author V. A. Ekimov
Format Journal Article
LanguageRussian
Published “ABV-press” Publishing house”, LLC 01.02.2015
Subjects
bevacizumab
metastatic colorectal cancer
Online AccessGet full text

Cover

More Information
Summary:Treatment of patients with metastatic colorectal cancer (mCRC)  is one of the priority questions in oncology. Despite the significant progress in chemotherapy treatment, development of target agents is the only way of further improvement of the results. Bevacizumab (Avastin) is the first biologic demonstrated it’s efficacy in 1st and 2nd therapy lines in mCRC patients and what’s more important – in continuation with first two serial chemotherapy lines.Author presents his own experience of prolonged bevacizumab (Avastin) therapy in several serial therapy lines in mCRC patient.
ISSN:2686-9594
DOI:10.17650/2220-3478-2013-0-2-48-51